



MARKET RELEASE

17 March 2017

Neuren Pharmaceuticals Limited

TRADING HALT

The securities of Neuren Pharmaceuticals Limited (the "Company") will be placed in Trading Halt Session State at the request of the Company, pending the release of an announcement by the Company. Unless ASX decides otherwise, the securities will remain in Trading Halt Session State until the earlier of the commencement of normal trading on Wednesday, 22 March 2017 or when the announcement is released to the market.

Security Code: NEU

Violetta Codreanu
ADVISER, LISTINGS COMPLIANCE (SYDNEY)



17 March 2017

Violetta Codreanu
ASX Compliance Pty Limited
20 Bridge Street
Sydney NSW 2000

By Email

Dear Violetta,

TRADING HALT REQUEST

The Directors of Neuren Pharmaceuticals Limited (ASX Code: NEU) hereby request a halt in trading of the Company's securities, effective until market opening on Wednesday 22 March 2017, or an earlier announcement by the Company.

The trading halt is requested pending an announcement regarding Neuren's Phase 2 clinical trial of trofinetide in Rett syndrome.

The Company is not aware of any reason why the trading halt should not be granted.

Yours sincerely

A handwritten signature in black ink, appearing to read "Jon Pilcher".

Jon Pilcher
CFO & Company Secretary